Christopher A. Seeger

The Earplug That Arrived With an Acquisition

The device at the center of the case was small enough to lose in a pocket: a dual-ended plug, olive green on one end and yellow on the other, worn one way or the other depending on the job.

Reversed in the ear, it was meant to do two things a soldier needs at once. One end blocked steady noise. The other was supposed to admit a shouted order while stopping the impulse of a rifle report — the millisecond spike that damages hearing.

It was sold to the United States military across roughly a dozen years, from 2003 to 2015, and issued widely enough that servicemembers who had never heard of the manufacturer had carried it in training and in Iraq and Afghanistan.

The design did not originate with 3M. It came to the company through its 2008 acquisition of Aearo Technologies, which meant the litigation that followed involved a product history predating the corporate defendant’s ownership of it — testing records, design decisions, and military correspondence generated by one company and inherited by another.

The claims consolidated before Judge M. Casey Rodgers in the Northern District of Florida as MDL 2885. More than 320,000 cases entered the proceeding, making it the largest multidistrict litigation by case count in the history of the federal system. Over 240,000 plaintiffs remained when the settlement was announced in 2023.

An affiliated entity sought Chapter 11 protection in 2022 in an effort to move the claims out of the MDL and into bankruptcy court. The petition was dismissed in 2023, and the cases returned to Pensacola.

Sixteen Trials in Fourteen Months

Before any of it could be settled, it had to be tried.

The parties conducted corporate, military, expert, and claimant-specific discovery, litigated evidentiary and expert challenges, briefed dispositive motions, and then went to trial sixteen times in fourteen months. Those trials produced nineteen jury verdicts addressing product identification, causation, hearing-loss evidence, damages, and competing expert testimony.

A bellwether program is not a sampling exercise for its own sake. It is a pricing mechanism. Each trial converts an abstract category — “a hearing-loss claim” — into a documented record of what the evidence actually looks like when a particular service history, a particular audiogram, and a particular expert are placed in front of twelve people.

Sixteen of those records, taken together, describe a range. They show which facts drive value, which are contested, which are provable from military files, and what it costs both sides to litigate any one of them to judgment.

Seeger and the other leaders used that developed record to negotiate common terms while preserving the distinctions among service histories, product-use evidence, audiograms, diagnoses, and injuries. The bellwethers supplied an evidentiary map. The work that followed was translating the map into rules that could distinguish among claims without requiring nearly 250,000 separate trials.

Ninety-Eight Percent

Seeger served on the plaintiffs' executive committee and as one of four Negotiating Plaintiffs' Counsel with Bryan Aylstock, Clayton Clark, and Daniel Gustafson. The resulting agreement provided up to $6 billion to resolve claims alleging hearing damage from the earplugs, payable in installments over a period of years rather than in a single transfer.

More than 249,000 claimants registered by the final registration date.

The agreement required participation by 98 percent of eligible claimants under its counting rules. Reported participation exceeded 99 percent.

That threshold is the hinge on which a mass settlement turns, and it explains why the design work matters as much as the number. A defendant paying to end litigation is buying finality; a program that leaves thousands of claims outside it has not delivered the thing being purchased. But participation cannot be compelled. Each claimant decides individually, with the advice of separate counsel, whether the program's terms beat the alternative of continued litigation.

Getting past 98 percent therefore requires rules that a claimant's own lawyer can read and evaluate: criteria that are legible, categories that track the evidence people actually possess, a route for the unusual case, and a review process for a determination the claimant believes is wrong.

Seeger carried the program from negotiation into operation, coordinating with the claims administrator, the allocation officials, the network of claimants' counsel, the data systems, and the court-supervised processes that governed each step.

By March 2024, the first $250 million had reached the settlement fund. Administrators had prepared payments for 86 percent of the 19,496 claimants then enrolled in the expedited-payment group, subject to the program's required review and payment sequence. Additional deposits supported later stages of distribution.

Two Doors

The agreement gave claimants a choice between two programs.

The Expedited Payment Program used scheduled award categories and a shorter documentary process. It traded individualized valuation for speed and certainty.

The Deferred Payment Program provided a more detailed evaluation of evidence and injury severity, with awards determined through a points system and defined categories. It traded speed for resolution that could account for a worse injury or a stronger record. Separate agreements addressed verdict and wave cases, whose procedural histories differed.

An Extraordinary Injury Fund sat alongside both, giving claimants a separate process to seek additional awards for qualifying injuries that the standard categories could not capture.

Claimants selected the path suited to their documentation and their injury evidence. Recorded tinnitus, hearing-loss testing, service and product-use records, and other defined criteria affected classification and value. Award notices and reconsideration procedures gave each claimant a way to have a determination reviewed before payment.

The structure reflects a fact about mass injury that averaging conceals. Two servicemembers who used the same earplug in the same year may hold entirely different claims — one with a documented audiogram at intake and separation, one without; one with tinnitus recorded in a medical file, one who never reported it. A program that pays them identically is inaccurate. A program that litigates the difference is unaffordable. The points and the categories exist to hold the middle.

First In, First Out

For expedited claims, BrownGreer assigned each claimant a first-in, first-out rank based on the date the claimant signed a release during registration. Finalized awards were then matched to available deposits in that sequence.

Money arrives in tranches, and awards are finalized on their own timetable. Something has to determine who is paid in one cycle and who is paid in the next, and that rule must be knowable in advance and identical for everyone.

A date-stamped queue does that work. It removes discretion from the sequencing question entirely, which is what allows a claimant's lawyer to answer "when" with a position rather than a guess.

The rules identified the documentation, review steps, payment instructions, and approvals required at each stage of distribution.

Who Holds the File

At this scale, settlement design becomes a question of custody. Every transfer of information — claimant to counsel, counsel to administrator, administrator to fund, fund to claimant — needs a defined record, a deadline, and an identified decision-maker. Where those are missing, files stall silently, and a stalled file at national scale means thousands of people waiting without an explanation.

The 3M program distributed those responsibilities among separate court-appointed roles.

3M funded qualified settlement funds used to pay claimants. ARCHER served as the court-appointed Settlement Administrator — acting as Claims Administrator, QSF fund administrator, and healthcare-lien administrator. BrownGreer served separately as Settlement Data Administrator for MDL-Centrality and claimant data. The court also appointed a Settlement Allocation Master and an EIF Special Master.

The division of labor was deliberate. The allocation master established and supervised the allocation methodology. ARCHER applied that methodology, administered the qualified settlement fund and claimant payments, and handled lien resolution. The EIF special master reviewed qualifying extraordinary-injury petitions and determined eligibility for additional awards.

Separating the entity that writes the rules from the entity that applies them, and both from the entity that hears exceptional cases, is what makes a program auditable. Each determination has an author who can be identified and a standard that can be checked.

After registration closed, the administrators kept working: correcting files, issuing determinations, processing reconsideration requests, managing first-in-first-out positions, and matching finalized awards to later deposits. For wave claimants, point values could be calculated only after the full pool was complete.

The Lien Problem, Solved First in Zyprexa

A settlement check is not the end of a claimant's obligations. If Medicare, Medicaid, the Department of Veterans Affairs, TRICARE, or a private insurer paid for treatment of the injury, those payers hold reimbursement rights against the recovery. Resolve them badly and the claimant faces demands months after the money has been spent — or the settlement fund faces exposure it never priced.

Seeger had built the answer to this problem two decades earlier. In the Zyprexa litigation before Judge Jack Weinstein in the Eastern District of New York, and then in Vioxx, he helped develop global lien-resolution administration: a process that folded Medicare, Medicaid, and other reimbursement obligations into settlement administration itself, so that approved claims moved through a defined resolution and distribution sequence rather than leaving each claimant to negotiate alone with a federal agency.

In the 3M program, registration data, supporting records, award review, lien resolution, payment priority, and funding were coordinated through a single court-supervised structure. Seeger's implementation work connected the negotiated agreement to the administrative steps required to issue awards and complete payments.

Vioxx and the Eighty-Five Percent Threshold

The 3M program was not the first time Seeger had negotiated an agreement whose viability depended on near-universal acceptance.

He served as co-lead counsel of the plaintiffs' steering committee in the Vioxx litigation, MDL 1657, before Judge Eldon Fallon in the Eastern District of Louisiana, and as one of the negotiating counsel who reached a $4.85 billion settlement with Merck in November 2007.

Vioxx had been prescribed to millions of patients before its 2004 withdrawal, and the litigation involved roughly 50,000 claimants across federal and coordinated state proceedings. The agreement conditioned Merck's obligation on participation by 85 percent of eligible claimants, and it evaluated claims against defined criteria — documented use, the nature of the cardiovascular event, its timing relative to use, and the medical records that established each.

The agreement provided an earlier model for common criteria, documented evidence, points-based valuation, an exceptional-case route, and lien resolution built into the administration. Sixteen years later, the 3M program applied related tools at roughly five times the claimant count.

Sixty-Five Years

Seeger also serves as co-lead class counsel in the National Football League concussion litigation before Judge Anita Brody in the Eastern District of Pennsylvania — a settlement structured on an entirely different principle from the ones above.

It has no aggregate cap. Rather than fixing a total and dividing it, the agreement defines qualifying diagnoses and award levels and obligates the NFL to pay every valid claim for the life of the program: a term of 65 years, long enough to cover retired players who were young men when it was approved and men not yet diagnosed when it began.

Qualifying diagnoses carry maximum award levels, with the highest reserved for ALS, and awards adjust for the player's age at diagnosis and his number of eligible seasons. A Baseline Assessment Program provided class members with neurological examinations at no cost, so that a player could establish his condition in the present rather than reconstruct it later.

The program has now paid more than $1.4 billion in monetary awards to retired players and their families, and it is still in the early decades of its term.

Seeger also negotiated the amendment that removed race-based demographic adjustments from the program's neuropsychological scoring protocols, which the court approved in 2022, and the revised protocols now govern the dementia claims that constitute the largest category of awards.

An uncapped, 65-year obligation raises administrative questions a fixed fund does not. Diagnostic standards evolve. Physicians retire. Records age. The settlement therefore required a claims system built to last for decades, with appeals, audit rules, provider networks, and procedures able to operate after the lawyers who designed them have stopped practicing.

Diesel, Ventilators, Pills

Seeger's mass-tort and class-action work also includes the Volkswagen diesel emissions litigation, the opioid litigation, Philips respiratory devices, proton-pump inhibitors, and Zyprexa. The matters have involved product-liability evidence, economic-loss claims, personal-injury claims, medical monitoring, public-entity claims, and settlement administration, each requiring a structure fitted to its own kind of harm.

The Volkswagen litigation resolved economic loss on a fleet: hundreds of thousands of vehicles whose owners were offered a buyback, a lease termination, or an approved emissions modification, plus restitution, with values keyed to model and mileage rather than to any individual's medical proof.

The Philips agreements used separate structures for economic-loss, personal-injury, and medical-monitoring claims — approximately $479 million for economic loss in 2023, and $1.075 billion for personal injury in 2024 with a further $25 million for medical monitoring. Device owners who had lost the value of a machine, patients alleging injury from degraded sound-abatement foam, and users seeking future surveillance rather than present compensation cannot be evaluated on the same criteria, and the settlement did not try.

His opioid work involved allocation and implementation for public entities and private defendants, where the claimant is a county or a city, the injury is a public cost, and the question is how a recovery gets spent on abatement rather than how it gets divided among individuals.

Across all of it, Seeger's role was the same: turn negotiated terms into operative rules. Define who qualifies, what evidence counts, how claims are valued and reviewed, which releases apply, and how payments move through distribution.

The Carpenter's Son

Seeger is the son of a union carpenter. He worked while attending school, took his B.A. at Hunter College and his J.D. at Cardozo School of Law, and began his career on the other side of the docket, as a corporate defense lawyer.

He founded Seeger Weiss in 1999.

He boxed as an amateur and later earned a black belt in Brazilian jiu-jitsu.